IDM Pharma to Present at BIOCOM Investor ... ( IRVINE Calif. Oct. 29 /- IDM Phar...)

IDM Pharma to Present at BIOCOM Investor Conference

Date:10/29/2007

IRVINE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI), a biotechnology company focused on the development of innovative cancer therapies, announced today that Timothy P. Walbert, president and chief executive officer, will present a corporate overview at the BIOCOM Investor Conference in San Diego on Thursday, November 1, 2007 at 2 p.m. PDT at the San Diego Marriott Del Mar.

A webcast of the presentation will be available live and following the presentation at http://www.idm-pharma.com.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

The presentation described in this press release will include forward-looking statements that reflect management's current views of future events including statements regarding the Company's plans to collect, analyze and submit additional Phase 3 data in an amended NDA for L-MTP-PE and to respond to other matters raised by ODAC and the FDA, the Company's confidence that the proposed NDA amendment will provide substantial evidence for the continued regulatory approval process, the review of the submissions for marketing approval of
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango

Post Your Comments:

IDM Pharma to Present at BIOCOM Investor ...( IRVINE Calif. Oct. 29 /- IDM Phar...)